(Q33305487)

25 July 2017

0 references

A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity (English)

1 reference

25 July 2017

0 references

1 reference

unsupervised clustering

1 reference

1 reference

Pamela C Sieving

5

0 references

author name string

Denise A Gonzales

1

1 reference

25 July 2017

Kelly J Norsworthy

2

1 reference

25 July 2017

Steven J Kern

3

1 reference

25 July 2017

Steve Banks

4

1 reference

25 July 2017

Robert A Star

6

1 reference

25 July 2017

Charles Natanson

7

1 reference

25 July 2017

Robert L Danner

8

1 reference

25 July 2017

language of work or name

English

0 references

publication date

14 November 2007

1 reference

25 July 2017

1 reference

25 July 2017

5

1 reference

25 July 2017

32

1 reference

https://scigraph.springernature.com/pub.10.1186/1741-7015-5-32

25 July 2017

0 references

cites work

Prevention of contrast agent-induced renal impairment in patients with chronic renal insufficiency and heart disease by high-dose intravenous N-acetylcysteine: a pilot-ministudy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

N-acetylcysteine and contrast-induced nephropathy in primary angioplasty.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Prophylaxis strategies for contrast-induced nephropathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Meta-analysis: Methods, strengths, weaknesses, and political uses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

N-acetylcysteine in the prevention of radiocontrast-induced nephropathy: clinical trials and end points

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Systematic review of the impact of N-acetylcysteine on contrast nephropathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

N-acetylcysteine in the prevention of radiocontrast-induced nephropathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Measuring inconsistency in meta-analyses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Quantifying heterogeneity in a meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Cystatin C: an improved estimator of glomerular filtration rate?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Meta-analysis. Unresolved issues and future developments

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Bias in meta-analysis detected by a simple, graphical test

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Discrepancies between meta-analyses and subsequent large randomized, controlled trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Operating characteristics of a rank correlation test for publication bias

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Meta-analysis in clinical research

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Publication bias in clinical research

21 June 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

21 June 2018

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

21 January 2018

Misleading meta-analysis

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Acetylcysteine and contrast agent-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Therapy of microcirculatory disorders in severe acute pancreatitis: what mediators should we block?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Prophylactic acetylcysteine usage for prevention of contrast nephropathy after coronary angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures--a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Comparison of N-acetylcysteine and fenoldopam for preventing contrast-induced nephropathy (CAFCIN).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair-a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Acetylcysteine for prevention of contrast nephropathy: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Interest of cystatin C in screening diabetic patients for early impairment of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

N-acetylcysteine for the prevention of kidney injury in abdominal aortic surgery: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-5-32

Renoprotective effect of high periprocedural doses of oral N-acetylcysteine in patients scheduled to undergo a same-day angiography.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Effectiveness of acetylcysteine in prevention of contrast nephropathy

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Absence of nephro-protective effect of acetylcysteine in patients with chronic renal failure investigated by coronary angiography

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Effectiveness of acetylcysteine on preventing renal dysfunction in patients undergoing coronary procedures

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Role of acetylcysteine in the prevention of contrast-media-induced nephrotoxicity

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC)

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2200657

Do iodinated contrast media interfere with renal tubular creatinine secretion?

31 October 2018

1 reference

12 December 2020

Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial

1 reference

12 December 2020

Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective cont

1 reference

12 December 2020

Renal failure after major angiography can be avoided with hydration

1 reference

12 December 2020

The effect of acute renal failure on mortality. A cohort analysis

1 reference

12 December 2020

Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality

1 reference

12 December 2020

Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics

1 reference

12 December 2020

Interactions between serum creatinine, volume status, N-acetylcysteine, and contrast-induced nephropathy

1 reference

12 December 2020

Identifiers

DOI

10.1186/1741-7015-5-32

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference